Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD4+ T cell receptors (TCRs) recognizing Hepatitis C Virus (HCV)-derived peptides are specialized protein complexes on the surface of helper T lymphocytes that identify viral antigens presented by Major Histocompatibility Complex (MHC) class II molecules (Source: Schulze Zur Wiesch et al., Journal of Experimental Medicine, 2012). These receptors play a pivotal role in the immune system's ability to control and clear HCV infection by initiating signaling cascades that lead to the production of critical cytokines, such as interferon-gamma and interleukin-2 (Source: Grakoui et al., Science, 2003). A robust and diverse CD4+ TCR response is strongly correlated with spontaneous viral clearance, whereas a weak or narrow response often leads to chronic infection and progressive liver disease, including cirrhosis and hepatocellular carcinoma (Source: Lauer et al., Journal of Virology, 2002). In the context of drug development, these TCRs are the primary targets for T-cell-based vaccines, such as the ChAd3-NSmut/MVA-NSmut prime-boost regimen, and experimental adoptive cell therapies aimed at restoring or enhancing the host's anti-viral immunity (Source: Swadling et al., Science Translational Medicine, 2014). Therapeutic interventions seek to expand the population of T cells bearing these specific receptors or to improve their functional sensitivity to viral peptides. However, challenges such as viral mutational escape and the potential for immune-mediated tissue damage must be carefully managed in clinical applications (Source: Walker, Nature, 2010).
Vaccines or adoptive therapies targeting these receptors aim to induce or restore the activation of HCV-specific CD4+ T cells. Upon binding to viral peptides presented by MHC class II, these TCRs trigger the release of Th1 cytokines (IFN-gamma, IL-2) and provide essential help to CD8+ cytotoxic T cells and B cells, ultimately leading to the suppression of viral replication and clearance of infected hepatocytes (Source: Grakoui et al., Science, 2003; Shoukry et al., Journal of Experimental Medicine, 2003).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CD4+ T cell receptor recognizing Hepatitis C Virus-derived peptides (HCV-specific CD4+ TCR) (HCV-specific CD4+ TCR).